Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma

Key facts

Sponsor

Children's Oncology Group

Principal Investigator

Jacqueline Kraveka, DO, M.D

Medical University of South Carolina

Intervention

doxorubicin hydrochloride(drug)

Enrollment

129 enrolled

Eligibility

20 years · All sexes

Timeline

2003 – 2014

Study locations (30)

• Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
• Phoenix Children's Hospital, Phoenix, Arizona, United States
• Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• Southern California Permanente Medical Group, Downey, California, United States
• Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
• Children's Hospital Central California, Madera, California, United States
• Children's Hospital of Orange County, Orange, California, United States
• Sutter Cancer Center, Sacramento, California, United States
• Kaiser Permanente Medical Center - Oakland, Sacramento, California, United States
• Rady Children's Hospital - San Diego, San Diego, California, United States
• UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
• Stanford Cancer Center, Stanford, California, United States
• Children's Hospital Center for Cancer and Blood Disorders, Aurora, Colorado, United States
• Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States
• Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Anaplastic large cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06561048
  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
  Corvus Pharmaceuticals, Inc.
• RECRUITINGPHASE1NCT06494371
  A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
  Ruijin Hospital
• RECRUITINGPHASE1, PHASE2NCT06137144
  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
  AstraZeneca
• ACTIVE NOT RECRUITINGPHASE1NCT04526834
  Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
  Tessa Therapeutics
• ACTIVE NOT RECRUITINGPHASE3NCT04881838
  CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL
  Children's Cancer Group, China
• ACTIVE NOT RECRUITINGPHASE2NCT02978625
  Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
  National Cancer Institute (NCI)
• RECRUITINGNCT04220970
  Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
  The Lymphoma Academic Research Organisation

See all trials for Anaplastic large cell lymphoma →